North Ryde, Australia Clinical Trials

A listing of North Ryde, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer

RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. PURPOSE: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer.

orchiectomy
epinephrine
antiandrogen therapy
antiandrogens
androgens
Sydney Cancer Centre at Royal Prince Alfred Hospital
 (7.5 away) Contact site
  • 401 views
  • 07 Nov, 2020
  • +8 other locations
A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Northern Cancer Insitute, St. Leonards
 (4.8 away) Contact site
  • 2496 views
  • 21 Sep, 2020
  • +209 other locations
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

The purpose of the study is to determine if the combination of niraparib with Abiraterone Acetate (AA) plus prednisone compared with AA plus prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC) provides superior efficacy in improving radiographic progression-free survival (rPFS).

Macquarie University Hospital
 (1.3 away) Contact site
  • 0 views
  • 23 Nov, 2020
  • +348 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in participants with mHSPC, the combination of pembrolizumab plus enzalutamide plus ADT is superior to placebo plus enzalutamide plus ADT with …

Chris OBrien Lifehouse ( Site 0300)
 (7.3 away) Contact site
  • 272 views
  • 25 Nov, 2020
  • +175 other locations
Continuous Monitoring of Prostate Position During Radiotherapy

This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating).

adenocarcinoma
external beam radiotherapy
prostate specific antigen
adenocarcinoma of prostate
Department of Radiation Oncology, Northern Sydney Cancer Centre
 (4.8 away) Contact site
  • 2 views
  • 08 Nov, 2020
  • 1 location
Focal Radiotherapy for Previously Treated Prostate Cancer Patients

To examine the feasibility, safety and toxicity of focal stereotactic radiation treatment (SBRT) for locally recurrent prostate cancer.

Royal North Shore Hospital
 (4.8 away) Contact site
  • 2 views
  • 15 Mar, 2020
  • 1 location
In Men With Metastatic Prostate Cancer What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy

This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic hormone-naive prostate cancer (mHNPC).

St Vincent's Hospital Sydney
 (8.2 away) Contact site
  • 0 views
  • 25 Nov, 2020
  • +3 other locations
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not previously treated with chemotherapy.

orchiectomy
renal function
pet/ct
liver metastases
conjugated bilirubin
St Vincents Hospital
 (8.2 away) Contact site
  • 0 views
  • 08 Oct, 2020
  • +3 other locations
Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B

Long-term safety follow-up for subjects with Hemophilia B and previously treated in the C0371005 (formerly SPK-9001-101) protocol

hemophilia
Royal Prince Alfred Hospital
 (7.5 away) Contact site
  • 96 views
  • 09 Dec, 2019
  • +8 other locations
A Phase I Gene Therapy Study of FP253/Fludarabine for Prostate Cancer

The primary objective of this study is to determine the safety and tolerability of a gene-directed enzyme prodrug therapy for prostate cancer. FP253 contains an ovine atadenovirus that expresses the E. coli enzyme purine nucleoside phosphorylase (PNP) under the control of a prostate-directed promoter. PNP converts systemically administered fludarabine (the …

orchiectomy
antiandrogen therapy
gonadorelin
biopsy of prostate
gonadotropin
St Vincent's Hospital, Sydney
 (8.2 away) Contact site
  • 90 views
  • 07 Nov, 2020
  • 1 location